NEOVACS NAMES NATHALIE THOMAS-PUJOL HEAD OF REGULATORY AFFAIRS

NEOVACS NAMES NATHALIE THOMAS-PUJOL HEAD OF REGULATORY AFFAIRS

Paris, June 3, 2014 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the appointment of Nathalie Thomas-Pujol as head of regulatory affairs.

Thomas-Pujol brings 20 years of regulatory affairs and clinical research experience in the pharmaceutical industry to Neovacs. In her new role, she will ensure that Neovacs' preclinical and clinical development plans are compliant with international regulatory requirements.

"We are proud to welcome such a talented professional to our team. Nathalie's appointment is a sign of confidence in the future of our company. As our research is growing and our products move toward later stages of development, our need for a dedicated regulatory expert has become increasingly apparent. Nathalie's skills and in-depth knowledge of regulatory affairs, as well as her experience with the EMA^[1] and FDA, are true assets for discussions with potential partners and in preparation for the future registration of our therapeutic products", said Neovacs CEO Miguel Sieler. 

Thomas-Pujol launched her career in clinical research at Aventis R&D where she managed multinational Phase I, II and III clinical trials for new products in development. Nathalie then moved to R&D and Regulatory Affairs within Sanofi-Aventis, where she held a variety of positions for nearly 15 years. Notably, Thomas-Pujol was responsible for new oncological, anti-infective and immunological products

She has extensive experience interacting with several health authorities including the European Medicines Agency and the U.S. Food and Drug Aadministration. Thomas-Pujol joined Cephalon in 2007, a wholly owned subsidiary of Teva since 2011, where she headed regulatory affairs for Europe, the Middle East and Africa. Nathalie holds a Pharmacist Doctorate from the University of Rouen in France and a Ph.D in toxicology from the University of Paris VII in France.

About Neovacs
Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by six patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFNalpha-Kinoid is being developed for the indication of lupus. Neovacs is also conducting preclinical works on IFNalpha-Kinoid in  certain chronic viral infections, VEGF-Kinoid in Age-related Macular Degeneration (AMD) and solid tumors, and IL-4-Kinoid for the treatment of allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr